The Precision Cancer Screening Navigation Program study, 'PC-SNaP', aims to focus limited resources on patients who are at increased risk for lower GI disorders which may include colorectal cancer. PC-SNaP will use a clinical machine learning algorithm to deliver an evidence-based patient navigator program to navigate barriers to colorectal cancer screening for patients living in North and West Philadelphia with an indication of an increased risk for lower GI disorders. We are collaborating with Medial EarlySign, an Israel-based clinical AI company, to carry out this one-of-a-kind precision outreach trial for those served by Penn Medicine with the goal of helping to identify those who would benefit from further evaluation.
Research Categories